Edwyn
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | $13,445 | $10,982 | $10,173 | $9,836 | $9,676 |
| Gross Profit | $11,639 | $8,872 | $7,895 | $7,302 | $7,366 |
| Operating Income | $4,550 | $2,841 | N/A | N/A | N/A |
| Net Income | $4,001 | $1,556 | $3,047 | $1,161 | $1,632 |
Over the past five years, Biogen’s revenue and gross profit have experienced a noticeable decline. In 2020, the company reported revenue of approximately 13.4 billion USD and gross profit near 11.6 billion USD. However, by 2021 revenue dropped to about 11.0 billion USD—an approximate 18% decrease—and gross profit similarly fell nearly 24% to 8.9 billion USD. The sharpest decline appears in operating income, which fell from 4.55 billion USD in 2020 to 2.84 billion USD in 2021, before being reported as zero in subsequent years. This absence of recorded operating income from 2022 onward warrants additional investigation, as it may reflect operational restructuring, reclassification of expenses, or accounting adjustments related to significant R&D investments typical in the biotechnology sector. In terms of net income, there are significant fluctuations. After a robust 4.00 billion USD in 2020, net income dropped steeply to 1.56 billion USD in 2021—a decline exceeding 60%. Although there was a partial rebound to 3.05 billion USD in 2022, figures again trended downward to 1.16 billion USD in 2023, followed by a modest increase to 1.63 billion USD in 2024. This volatility in net income suggests that despite relatively strong gross profit margins, factors affecting operating income have deeply impacted the company’s bottom line. Overall, while Biogen continues to generate solid revenues and maintain significant gross margins, the erratic trends in operating and net income raise questions about its financial management and sustainable profitability amid evolving market conditions and a competitive biotechnology landscape.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.